Expert Comparison: Wegovy vs Mounjaro at Treatment Week 13
Understanding 1.7mg Wegovy vs Mounjaro for Prescription Weight Loss
When comparing 1.7mg Wegovy vs Mounjaro for prescription weight loss, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone, whilst Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Both are prescription-only medicines licensed by the MHRA for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities.
At the 1.7mg Wegovy stage, you're in weeks 13-16 of treatment, approaching the final maintenance dose of 2.4mg. This represents a crucial period where treatment effects are typically accelerating, and planning your transition to long-term therapy becomes essential. Mounjaro follows a different dosing schedule, starting at 2.5mg and escalating to maintenance doses of 10mg or 15mg, making direct dose comparisons between 1.7mg Wegovy vs Mounjaro less meaningful than understanding their distinct treatment pathways.
1.7mg Wegovy vs Mounjaro: UK Pricing and Value Analysis
The cost comparison between 1.7mg Wegovy vs Mounjaro reveals important considerations for your treatment budget. Wegovy 1.7mg costs £139.99 as a single pen, whilst Mounjaro's equivalent treatment stage pricing varies based on your specific dose requirements. EverydayMeds offers the Elevate Duo bundle containing both 1.7mg and 2.4mg Wegovy pens for £369.99, providing seamless transition to maintenance therapy with Reliable Supply continuity.
Returning customers benefit from the DOSE25 discount code applied at checkout, whilst new patients use FIRST40 to reach these competitive prices. The Consistency 1.7mg bundle (two 1.7mg pens) costs £309.99, ideal if your prescriber recommends staying at this dose longer. Both Wegovy and Mounjaro are available from EverydayMeds — your prescriber can help determine which offers better value for your specific clinical situation.
Clinical Evidence: 1.7mg Wegovy vs Mounjaro Weight Loss Data
Clinical trial evidence for 1.7mg Wegovy vs Mounjaro comes from separate study programmes with different designs and populations. In the STEP trials, patients taking Wegovy alongside diet and exercise experienced average weight loss of approximately 15% at 68 weeks (Wilding et al., NEJM, 2021). The 1.7mg dose represents the penultimate step in this escalation protocol, where therapeutic effects are building towards peak efficacy.
Mounjaro's SURMOUNT trials demonstrated significant weight loss outcomes, though direct comparison with Wegovy percentages would be inappropriate due to different trial methodologies and patient populations. Both medications have shown cardiovascular benefits in their respective studies, with Wegovy's SELECT trial revealing a 20% reduction in major cardiovascular events. Your prescriber can evaluate which evidence base best aligns with your clinical profile when comparing 1.7mg Wegovy vs Mounjaro options.
How 1.7mg Wegovy Works for Prescription Weight Loss
Wegovy's mechanism centres on GLP-1 receptor agonism, mimicking the action of glucagon-like peptide-1, a hormone naturally released after eating. At the 1.7mg dose, semaglutide binds to GLP-1 receptors in your brain's appetite centres, particularly the hypothalamus, reducing hunger signals and promoting satiety. This leads to decreased food intake as you feel fuller after smaller portions and experience reduced cravings between meals. The once-weekly injection provides sustained therapeutic levels, maintaining appetite suppression throughout the dosing interval. Unlike rapid-acting appetite suppressants, Wegovy works gradually to reset your appetite regulation, supporting sustainable weight management alongside lifestyle modifications.
Ordering 1.7mg Wegovy vs Mounjaro: Streamlined Process
Accessing either 1.7mg Wegovy or Mounjaro through EverydayMeds begins with our 3-minute online clinical assessment, designed to evaluate your eligibility and treatment history. Our prescribers review applications within 3 working days (or 24 hours with express service), ensuring thorough evaluation of your medical suitability for either treatment option. Once approved, both medications are dispatched via next-day delivery using cold-chain transportation to maintain temperature integrity throughout transit. The assessment covers your current dose progression, any side effects experienced, and helps determine whether continuing with 1.7mg Wegovy vs switching to Mounjaro aligns with your treatment goals. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance and professional oversight throughout the process.
Storage Advantages: 1.7mg Wegovy vs Mounjaro Practical Differences
Storage requirements present a notable difference when comparing 1.7mg Wegovy vs Mounjaro for practical daily use. Wegovy pens can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, whilst Mounjaro pens are limited to 21 days at room temperature. Both require refrigeration at 2-8°C before first use, but Wegovy's extended temperature tolerance offers greater flexibility for travel, work schedules, or situations where refrigeration access is limited. The FlexTouch pen system used for Wegovy provides clear dose confirmation and ergonomic injection experience. Each pen contains four doses, administered weekly, with clear visual indicators for dose setting and completion. This storage advantage can influence treatment adherence and lifestyle compatibility when weighing 1.7mg Wegovy vs Mounjaro options.
Transition Planning: 1.7mg Wegovy vs Mounjaro for Long-Term Success
The 1.7mg Wegovy dose represents a pivotal moment in treatment planning, as you're just one step away from the 2.4mg maintenance dose where long-term therapy typically continues. This transition phase is crucial for establishing sustainable results and evaluating whether Wegovy's mechanism and dosing schedule suit your lifestyle and clinical response. Some patients may consider switching to Mounjaro at this stage if their response has been suboptimal or if they've experienced persistent side effects.
Planning your transition involves considering both immediate and long-term costs, storage requirements, and injection preferences. The Elevate Duo bundle specifically addresses this transition need, providing both your current 1.7mg dose and next-stage 2.4mg dose in one order. Your prescriber can assess whether continuing with Wegovy or transitioning to Mounjaro offers better prospects for sustained weight management. Both options represent valid long-term strategies, with the choice depending on individual clinical factors rather than superiority of either medication.
Secure Your 1.7mg Wegovy vs Mounjaro Treatment Today
Making your decision between 1.7mg Wegovy vs Mounjaro doesn't require immediate commitment to one option permanently — our prescribers can guide you through either pathway based on your clinical assessment results. New customers use code FIRST40 at checkout, whilst returning patients apply DOSE25 to access our competitive pricing. The streamlined ordering process at https://everydaymeds.co.uk/products/wegovy-1-7mg ensures rapid access to your chosen treatment with professional oversight. Both medications represent evidence-based approaches to prescription weight loss, supported by comprehensive clinical trials and MHRA licensing. Our clinical team provides ongoing support throughout your treatment journey, helping optimise your chosen therapy for maximum effectiveness and safety. Start your assessment today to determine which option best supports your weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
